PlA1/A2 polymorphism of platelet glycoprotein IIIa and risk of cardiovascular disease

Status and perspectives of biomarker validation for diagnosis, stratification, and treatment.

Public health·2020

Metabolic syndrome detection with biomarkers in childhood cancer survivors.

Endocrine connections·2020

Reliability and consistency of a validated sun exposure questionnaire in a population-based Danish sample.

Preventive medicine reports·2018

International collaborative study for the calibration of proposed International Standards for thromboplastin, rabbit, plain, and for thromboplastin, recombinant, human, plain.

Journal of thrombosis and haemostasis : JTH·2017

The validated sun exposure questionnaire: association of objective and subjective measures of sun exposure in a Danish population-based sample.

The British journal of dermatology·2016

Symptom load and individual symptoms before and after repair of parastomal hernia: a prospective single centre study.

Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland·2016

Izalontamab brengitecan versus platinum-based chemotherapy in EGFR-mutated advanced non-squamous non-small-cell lung cancer after progression on third-generation EGFR tyrosine kinase inhibitors (PANKU-Lung01): a multicentre, randomised, open-label, phase 3 trial in China.

Lancet (London, England)·2026

Sacituzumab tirumotecan versus treatment of physician's choice in previously treated endometrial cancer (TroFuse-005/ENGOT-en23/GOG-3095): a randomised, open-label, phase 3 trial.

Lancet (London, England)·2026

Izalontamab brengitecan for HR+/HER2- breast cancer in China (PANKU-Breast01): a randomised, phase 3 trial.

Lancet (London, England)·2026

First-line pembrolizumab versus carboplatin plus paclitaxel in participants with mismatch repair-deficient advanced or recurrent endometrial cancer (KEYNOTE-C93/GOG-3064/ENGOT-en15): interim analysis of a multicentre, open-label, randomised, active-comparator controlled, phase 3 trial.

Lancet (London, England)·2026

Ruzaltatug rezetecan versus chemotherapy for EGFR-mutated advanced non-small-cell lung cancer progressing after EGFR tyrosine kinase inhibitor therapy (HERON-Lung01): interim analysis of a randomised, open-label, phase 3 trial in China.

Lancet (London, England)·2026

14-day versus 28-day trifluridine-tipiracil plus bevacizumab for refractory metastatic colorectal cancer (PRABITAS): a pragmatic, multicentre, open-label, randomised, phase 3, non-inferiority trial in Japan.

Lancet (London, England)·2026

Generation and Characterization of Single-Domain Antibodies Against the D-Antigen of Sabin Poliovirus Types 2 and 3.

Viruses·2026

Multifaceted Regulation of Tea Astringency: A Review of Intervention Pathways by Co-Existing Flavor Components.

Molecules (Basel, Switzerland)·2026

Simplifying PA Quantification: A Unified Enrichment and Reduction Workflow for Retronecine-Based Quantification of Pyrrolizidine Alkaloids in Phyto Samples.

Molecules (Basel, Switzerland)·2026

Mechanisms, Discovery Strategies, and Emerging Opportunities for AI-Assisted Design of Peptides in Cosmetics and Skin Health.

Pharmaceuticals (Basel, Switzerland)·2026

Correction: Phan et al. Injectable Hydrogel Based on Protein-Polyester Microporous Network as an Implantable Niche for Active Cell Recruitment. Pharmaceutics 2022, 14, 709.

Pharmaceutics·2026

Molecular Interactions of Bioactive Peptides with Proteins and DNA.

Pharmaceutics·2026

Related Experiment Videos

PlA1/A2 polymorphism of platelet glycoprotein IIIa and risk of cardiovascular disease

Related Concept Videos

Status and perspectives of biomarker validation for diagnosis, stratification, and treatment.

Metabolic syndrome detection with biomarkers in childhood cancer survivors.

Reliability and consistency of a validated sun exposure questionnaire in a population-based Danish sample.

International collaborative study for the calibration of proposed International Standards for thromboplastin, rabbit, plain, and for thromboplastin, recombinant, human, plain.

The validated sun exposure questionnaire: association of objective and subjective measures of sun exposure in a Danish population-based sample.

Symptom load and individual symptoms before and after repair of parastomal hernia: a prospective single centre study.

Izalontamab brengitecan versus platinum-based chemotherapy in EGFR-mutated advanced non-squamous non-small-cell lung cancer after progression on third-generation EGFR tyrosine kinase inhibitors (PANKU-Lung01): a multicentre, randomised, open-label, phase 3 trial in China.

Sacituzumab tirumotecan versus treatment of physician's choice in previously treated endometrial cancer (TroFuse-005/ENGOT-en23/GOG-3095): a randomised, open-label, phase 3 trial.

Izalontamab brengitecan for HR+/HER2- breast cancer in China (PANKU-Breast01): a randomised, phase 3 trial.

First-line pembrolizumab versus carboplatin plus paclitaxel in participants with mismatch repair-deficient advanced or recurrent endometrial cancer (KEYNOTE-C93/GOG-3064/ENGOT-en15): interim analysis of a multicentre, open-label, randomised, active-comparator controlled, phase 3 trial.

Ruzaltatug rezetecan versus chemotherapy for EGFR-mutated advanced non-small-cell lung cancer progressing after EGFR tyrosine kinase inhibitor therapy (HERON-Lung01): interim analysis of a randomised, open-label, phase 3 trial in China.

14-day versus 28-day trifluridine-tipiracil plus bevacizumab for refractory metastatic colorectal cancer (PRABITAS): a pragmatic, multicentre, open-label, randomised, phase 3, non-inferiority trial in Japan.

Generation and Characterization of Single-Domain Antibodies Against the D-Antigen of Sabin Poliovirus Types 2 and 3.

Multifaceted Regulation of Tea Astringency: A Review of Intervention Pathways by Co-Existing Flavor Components.

Simplifying PA Quantification: A Unified Enrichment and Reduction Workflow for Retronecine-Based Quantification of Pyrrolizidine Alkaloids in Phyto Samples.

Mechanisms, Discovery Strategies, and Emerging Opportunities for AI-Assisted Design of Peptides in Cosmetics and Skin Health.

Correction: Phan et al. Injectable Hydrogel Based on Protein-Polyester Microporous Network as an Implantable Niche for Active Cell Recruitment. Pharmaceutics 2022, 14, 709.

Molecular Interactions of Bioactive Peptides with Proteins and DNA.

Related Experiment Videos

PlA1/A2 polymorphism of platelet glycoprotein IIIa and risk of cardiovascular disease

Related Concept Videos

Related Articles